Allergan, Inc. v. Sandoz, Inc., No. 16-1085 (Fed. Cir. Mar. 17, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Appellant Allergan, Inc. (“Allergan”) appeals the final decision of the U.S. District Court for the Middle District of North Carolina (“District Court”) dismissing its patent infringement ca se against Sandoz, Inc. et al. (“Sandoz”) with prejudice based on collateral estoppel and declaring several claims of Allergan’s patent invalid as obvious. We affirm-in-part and reverse-in-part. B ACKGROUND This case comes to our court with a lengthy procedur- al history involving both parties and six related patents: U.S. Patent Nos.